Acrivon Therapeutics to Present Phase 1 ACR-2316 Data
Acrivon Therapeutics says it will present Phase 1 data on its ACR-2316 cancer drug at the EORTC-NCI-AACR Symposium.
Related stories
Kakao Plans KRW 150 Billion Share Cancellation
Kakao plans to cancel shares worth KRW 150 billion.
M impact | EQUITY | Nov 05, 2026, 12:10 AM UTC
Toyota Motor shares rise 7.4%
M impact | EQUITY | Nov 05, 2026, 12:06 AM UTC
Global market picture: S&P 500 +1.65%, Nasdaq 100 +0.72%; EUR/USD +0.41%, WTI -8.05%
Global market picture. US index futures: S and P futures is up 1.65 percent, Nasdaq futures is up 0.72 percent, Dow futures is up 3.14 percent and Russell futures is up 1.48 percen
M impact | EQUITY | Nov 05, 2026, 12:06 AM UTC
South Korea’s KOSPI falls 2%
M impact | EQUITY | Nov 05, 2026, 12:05 AM UTC
KOSPI falls 2%
M impact | EQUITY | Nov 05, 2026, 12:05 AM UTC
NAB Full-Year Cash Profit Misses Estimates as Provisions Rise
Australia's NAB reported full-year cash profit below estimates and higher provisions.
M impact | EQUITY | Nov 04, 2026, 11:59 PM UTC